Introduction Whyt hismeta-analysis?
Elevated blood pressureisafrequentdiagnosisin the elderlyand -o wing tod ebilitating complicationss uchas stroke orheart attack-aleading publichealthi ssue worldwide. The population of 65years and olderhas the highest prevalenceo fh ypertension and the lowest control rates [1] .According tothe WHO/ISH classification hypertension isdefined asdiastolicb lood pressure >90mmHgo rs ystolicb lood pressure>140mmHg. Repeated standardized readingss hould betaken after 5min in the sitting position underpracticeconditions. Undert heseconditions,hypertension occurs in 70 %o f the elderlyin Europe and in 60 %-70 %ofelderlyAmer-icans [2] .
Abstract
The benefits of lowering blood pressure areo bvious fort he population uptothe age of 65years,b ut whetherand,if so, whichtreatmentisbeneficiali nthe very elderlypopulation remainss till amatter of debate. Weconducted ameta-analysis of randomised controlled clinicaltrials withd uration of atleast 12monthsand the analysisof cardio-and cerebrovascularendpoints in participants aged 75years and over.
MEDLINE, CENTRAL (Cochrane CentralRegisterof Controlled Trials)and the WHO-ISH Collaboration registerw ere searched until October2 0,2009. Further, referencesfrom reviews,trialsand previouslypublished meta-analysesw ere analysed. Atotalo f1 0s tudiesw erei ncluded providing morbidity and mortality datawithatotalo f8667 participants in the meta-analysis,withseparateanalyses fors tudieson isolated systolichypertension. Therewere1 48 non-fatalstrokes and 287cardiovascularmorbidity and mortality events among treated patients, compared with1 76 non-fatalstrokes (p =0.02)and 366 cardiovascularmorbidity and mortality events (p =0.0001) among control patients.Ratesof heart failureweresignificantlyreduced (64 vs. 121events; p=0.00001),totalm ortality remained unchanged (oddsr atio 0.97). Further,9studiesw ith6933 participants werei ncluded in the systematicreviewof blood pressurereduction trials.The average blood pressureachieved att he end of the studiesw as164/83mmHgi nthe placebog roupand 150/83mmHgi nthe treatmentgroup. Att he beginning of the studyblood pressurewas170.6/ 88.6mmHgi nthe placebog roupand 175.4/94.6mmHginthe treatmentgroup. Changesw ereo nlys ignificantforsystolic blood pressurei nthe treatmentgroup (p =0.0008).
Treating healthysubjects aged 75years and olderw ithm oderatetosevereh ypertension reducesnon-fatalstrokes,c ardiovascularmorbidity and mortality and the incidenceofheart failurebut doesnot change totalm ortality.
Beneficialclinicale ffects of treatmentof arterialh ypertension havebeen showni namultitude of clinical studiesformiddle-aged patients and in thoseo ver 60 years of age. However,whethertreatmentisstill beneficiali np atients over80y ears remainsamatterof debate. Manypatients of thisage groupremain untreated, havei nadequatelycontrolled hypertension oraretreated withinappropriatedrugs [3] .InGermany,forthe age groupofthe >75yearold men and women aprevalence of arterialh ypertension of about 80%could beo bserved;of those,only80%wered iagnosed,a nd only 20 %treated totarget [4] .Despitee videncef orpositive treatmenteffects,thereareconcernsabout anincreased riskf orevents in patients withl owblood pressureand severaltrialshavebeen published describing thisr elationship asJ-shaped. Especiallyin the vulnerable elderly thisu ncertainty isleading toreluctancei nthe useo f antihypertensiveagents [5] .The importanceo fanswering theseq uestionsisr ising withthe factt hatt he octogenariansarethe most rapidlygrowing segmentof our population [6] .
Until 1999,dataon the protectivee ffects of different antihypertensived rugsin hypertension in the very elderlyhavebeen limited toasubgroupanalysisof trials originallydesigned fort he age groupo f60 years and older [7] .Sincethen,fewclinicaltrialshavebeen conducted toshed lighton thisimportantquestion,a nd thereforeanewcomprehensivel iteraturesearch seemed toben ecessary.
Thisisnotauniqueattemptasothermeta-analyses on the same subjectexist,forexample [7] [8] [9] [10] [11] [12] , and recentlyasimilaranalysisbyBejan-Angoulvat etal. [13] . Musini etal. collected results of clinicaltrialsin people 60 years and olderand alsoconducted asubanalysisfor the age group8 0y ears and older [14] .Wee xtended the inclusion criteriatothe age of 75years and alsoaccepted non placebo-controlled trials.Thesee xtensions of inclusion criteriawered one in the lightof the preponderanceo fo ne recentt rial,the HYVET-trial [15] to cope withi ts obvious overruling in the meta-analysis byMusini etal. [14] .
The recentanalysisbyBejan-Angoulvat etal. [13] did notinclude the JATOS trial [16] .Withthisminordifferencei nm ind,its till seemsnecessary toi ndependently demonstratecongruentr esults on thisimportantmatter.
2.Methods
The conductand the presentation of thismeta-analysisarei n accordancewiththe PRISMA statement [17] .
Searchstrategy
The searchi ncluded the electronicdatabasesof MEDLINEa nd CENTRAL (Cochrane CentralRegisterof Controlled Trials)until October2 0,2009( no initiation limits)and,in addition,the WHO-ISH Collaboration register(August 1997). The trialsregisters "clinicaltrial.gov"and "controlled-trials.com"h avebeen searched.The internethasbeen searched using "scholar.goo- The searchstrategyfors earching the otherdatabaseswas: "Hypertension" and "Blood pressure" and "Therapy"and "Elderly".
Thiss earchl ed to1 092hits.Both,title and abstractt ext of eachrecordh avebeen evaluated. Inaddition tothe studies used in the subgroupmeta-analysisof Gueyffier etal. [7] , three clinicalstudies(i. e.,the HYVET trial,H YVET-Pilott rialand JA-TOS trial [15, 18, 16] )m ett he inclusion criteria(see below)f or the actualm eta-analysison clinicale ndpoints.The search strategyfors earching the CENTRAL databasewas:
"Hypertension" and "Blood pressure" and "Therapy"and "Elderly".
Thiss earchl ed to697hits.Out of these,26 trialshaven ot been found in the MEDLINE-search,but did notreport relevant clinicale ndpoints.Four of thesetrialsarei ncluded in the analysisof blood pressurelowering effects.
2.2Selection criteria
Randomised controlled trialson clinicale ndpoints of atleast one yearduration in hypertensivepatients aged 75years oroldercomparing antihypertensivedrugtherapywithplaceboorno specialtreatmentand assessing cardiovascularmorbidity and mortality outcomeswereincluded. All trialsfulfilling the inclusion criteriawerei mported intoane lectronicb ibliographyas full text and arranged underpredetermined conditions.Randomised controlledtrialsof atleast sixw eeksduration in hypertensivep atients aged 75years oroldercomparing antihypertensived rugtherapyw ithp laceboo ractivetreatment, assessing efficacy(blood pressurereduction) and tolerability wereused in the analysison blood pressurelowering effects.
Typesof participants
Men and women of atleast 75years witharterialsysto-diastolic orisolated systolichypertension werei ncluded. Hypertension hadtobed efinedass ystolicb lood pressureo fatleast 140mmHgand/ordiastolicblood pressureofatleast 90mmHg.
2.2.2Typesof interventions
Acceptable drugtherapyincluded:a ngiotensin-converting enzyme (ACE)i nhibitors,a ngiotensin receptorantagonists,b etaadrenergicb lockers,c ombined alpha-and beta-adrenergic blockers,calcium-channel blockers,diuretics,alpha-adrenergic blockers,centralsympatholytics,directvasodilators,peripheral adrenergica ntagonists.
2.2.3Datacollection and analysis
Outcomesassessed weretotalm ortality,totalcardiovascular morbidity and mortality,c ardiovascularmortality,fataland non-fatalstrokes,coronary heart diseasemorbidity and mortality,coronary heart diseasemortality,a nd heart failure.
Measuresassessed forblood reduction trialsweremeansand standardd eviationsof decreasei nsystolica nd diastolicb lood pressurecomparing top laceboo rno therapy,a nd assessing the reported adversee vents.Unfortunately,dataon renalf ailurewereinconsistentin thesestudies,and were,thus,notana- lysed. Nog lobalq uality scoring schemesfort he assessmentof the clinicaltrialconductwasused;however,importantindividualparameters of methodologicalquality havebeen assessed in detail. Thesei ncluded randomisation,a llocationconcealment, methodsof blinding,percentof lost tof ollow-up. Eachd ocumentw aschecked separatelybyasingle person fort he parameters mentioned above.
2.3Statistics
Analysesof outcomesw erebased on intention-to-treatr esults. The RevMan( ReviewManager)softwarewasu sed (RevMan Version 5.0Copenhagen:The NordicCochrane Centre,The Cochrane Collaboration,2008),forstatisticsthe SAS softwareVersion 9.2of the SAS System forWindows Copyright2009,SAS InstituteInc.(USA).
Efficacyof eachstudywasdescribed byriskratiosand confidenceintervals.Heterogeneity wastested bythe I2Test.Pooled riskd ifferencesobtained from afixed-effects model wereconverted ton umbers needed totreatu sing NNT =1/riskd ifference. Wecalculated control rates,i. e. the numberof events in the control group,toestimatethe aggregatepopulation riskfor patients included in the individualtrials.Asnotall trialscontained all variablesanalysed,numbers of trialsincluded in the analysesfort he various parameters maydifferasindicated in the legends.Meansand standardd eviationsof blood pressure reduction of eachi ncluded studyw erecalculated and compared in aregression analysis.
3.Results
Ten studieson endpoints withatotalo f8 667 participants werei ncluded. Out of thesetrials,atotalo fseven havebeen included in the subgroupm eta-analysisu tilizing the INDANA database [7] .The HYVET trialand the HYVET-pilott rialwerep ublished in 2008and 2003, respectively,the JATOS triali n2008 [15, 18, 16] .The SHEP trial,the STOP trialand the SYST-EUR trialh ave been published after1990,the remaining four studies before1 990.
Sixof thesestudiesw erep lacebo-controlled,twostudiesobservation controlled [18, 19] , one studycontrolled byfree therapy [20] ;one studycompared strict therapy versus mild therapy [16] .Three trialswereespeciallydesigned forparticipants withisolated systolichypertension [9, 21, 22] .60 %werefemale. The prevalence of smokers ranged from 4-11 %,of stroke from 3-10%, of myocardiali nfarction from 3-10%and of diabetes mellitus from 7-24%.The age distribution ranged from 75-102 years withamediano f8 3y ears.Most of the participants wererecruited from industrialised countries.All exceptt he CASTEL trialwerem ulticenters tudies.
Dataof non-fatalo utcomesfrom the EWPHE trial havenotbeen included in our analyses,sincethesedata aresubjectt oac ensoring bias [23] .Less than1 0%o f patients werel ost tof ollow-upi nall trials.Therearesix studiesmentioning the method of blinding,eights tudiesdescribing the method of randomisation and four studiesdescribing the method of allocation concealment.Inmorethan70 %oftrials,athiazide-like diuretic wasfirst line treatmentin the observation group. All trialsused astepped careapproachtoreachatreatment effect.InSHEP pilot,S HEP, EWPHE and HYVET, treatmentw ass tarted onlyon thiazide diuretics,in STOP and CASTEL itw ass tarted on eithert hiazide diureticor b -blocker [15,20 -24] .
Coope and Warranderu sed b -blockers,only,a nd in SYST-EUR calciumchannel blockers plus ACE-inhibitors wereapplied [9, 19] .InHYVET pilotone treatment armwass tarted on adiuretica nd anothert reatment armo nanACE-inhibitor.The thirdtrialarmaimed for observationsw ithout specifictherapy [18] .Ino ur metaanalysisw ecombined the twotreatmentarmsw ithactivetherapyand compared them against the observation therapyarm. Second and thirdl ine drugsincluded diuretics, b -blockers,A CE-inhibitors,c alciumchannel blockers and centrallyacting antiadrenergica gents. The results of the meta-analysisarecompiled in Table 1 .
The relativeriskf ornon-fatalstroke wasr educed to 0.78 ( Fig. 1) . Omitting the JATOS study,thiseffectbecomeseven morep ronounced (0.68). Heterogeneity was44 %f ort hisendpoint.Fors troke mortality atrend towardst reatmentcausing ariskreduction of 0.83w as noted. Relativeriskreduction forheart failurewas0 .49 (Fig. 2) . Heterogeneity was3 3%i nthe I2Test.Formorbidity and mortality bycardiovasculardisease,relative riskreduction was0 .75. Inthe three ISH trialsr iskreduction wasless pronounced withariskreduction of 0.77.Formorbidity and mortality bycoronary heart diseaserelativeriskwas0.73.Stroke mortality wasinsignificantlychanged to0.83.Mortality of coronary heart diseaseshowed ariskreduction of 0.79;however,there wereonlytwostudiesaiming atthisoutcome. Mortality of cardiovascularconditionss howed adiscreteriskreduction of 0.94. Fort otalm ortality,the riskwasat0 .97 (Fig. 3) withatendencytoanincreased treatmenteffect in the non-ISH studies(0.93). Without the HYVET-trial, arisko f1 .11 wasmeasured. Totalm ortality remained unchanged (0.97). Nine trialson blood pressurel owering efficacyand tolerability profile of atleast sixw eeksduration were found in addition tothe HYVET and HYVET pilott rial; the efficacyof blood pressurereduction wasanalysed in 11 trials.The blood pressurecharacteristicsof the othereightt rials'e valuation endpoints included in this revieww eren otavailable. Wei ncluded 6933 participants in total,4974p articipants in the treatmentgroup and 1959 participants in the control group,respectively. The mediand uration of follow-upi s6 0w eeks,ranging from 6-208weeks.
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Inthe placebog roupsystolicb lood pressurewas 170.6mmHgand diastolicb lood pressure8 8.6mmHg att he studybegin. Thesef iguresw ere1 64.6mmHgand 83.6mmHgats tudyend.
Inthe activetreatmentgroupsystolicb lood pressure changed from 175.4 to1 50mmHg,diastolicb lood pressuref rom 94.6t o8 3mmHg. Onlyt he activetherapy groupshowed astatisticallysignificanteffecton the systolicb lood pressurecompared withp lacebo (p =0.0008). Regression analysisdemonstrated thatt he treatmenteffectfors ystolicb lood pressurewass ignificantlymorep ronounced in the trialsconducted after the year2 000 (p =0.0015). Compared top lacebo,every single drugclass hadastatisticallys ignificanteffecton the reduction of systolicb lood pressurewithP-values between 0.0016-0.0042.Furthermore,a ctivetherapy showed asignificanteffecton diastolicb lood pressure valuescompared top lacebo( p=0.043). The effectof bblockers compared withp laceboo nthe diastolicb lood pressurei nthe presentanalysisisnots ignificantlydifferent(p =0.7349). All otherdrugclassess hows ignificanteffects compared withp lacebo( p=0.034-0.01). Becauseo fthe small numbers of trialp articipants receiving specificdrugclassest he comparison of results obtained withparticulardrugclassesw asnotfeasible.
Discussion
Outcomesareclearlyimproved byantihypertensive treatment; thisappliest od isabling and restricting conditionslike stroke,heart attackand heart failure. The reduction in fataland nonfatalstroke found herei sconsistentw iththe results in the analysisconducted by Gueyffier etal. [7] and Bejan-Angoulvat etal. [13] .These results arealsosimilarbut slightlys mallerin sizethan in the age groupo fthe 60 -70 yearold participants,a s described byMulrow etal. [25] .However,aconsider- able heterogeneity fornonfatalstroke should betaken intoaccount(p <0.07).
The absentimpactof treatmenton deathf rom any causei sin line withresults from ref. [46] .Thislacko f effectisr emarkable,a sareduction of majorcardiovascularendpoints part of whichm aybel ethalshould be reflected bylowerglobalm ortality asw ell. Ratesof deathbys troke range ashigh as50%i nthe age group in literature [26] .Thisabsenceo fe ffecton overall mortality mayreflectthe factthatthe studiesareunderpowered regarding thisrarerevent; on the otherhand,there iss till concerno fcausing harmtothe very elderly.Increased mortality of anycauseand of deathf rom stroke byantihypertensivetreatmentasr esults of J-curvetype effects havep ointed ton egativeo utcomesin overtreated individuals [5] .Deathfrom anycausewassignificantlyr educed onlyin the HYVET studyand death caused bys troke onlyin twoo thers tudies(SHEP and SHEP pilot). Removing the HYVET trial,the riskofdeath isnots ignificantlyaffected byactivetreatment.Ast his trialaccounts for54 %o fthe weightin thismeta-analysis,itisworthtodiscuss whethert histrialshould beg iven apriority in the evaluation of thisparameter,a nd would besufficientt osubstantiatee ven the mortality effect.Also,aconsiderable heterogeneity (p <0.06)e xists fort hisparameter.The factt hatnotonlyplacebocontrolled trialsbut alsoo pen and activecontrol trials werei ncluded,c ertainlycontributed tothisheterogeneity.
Ast he results of the HYVET trialsuggest,prescription of newerdrugstoelderlyand very elderlypatients might leadtoalargerr iskreduction. Increased intensity of antihypertensivetherapyand blood pressurel owering between the groupscould beafurtherexplanation for the largerr iskreduction. The meta-analysisbyBejanAngoulvat etal. [13] wasperformed including the subgroupanalysisfrom Gueyffierand the HYVET trialwith totalm ortality ast he main outcome. The authors suggest apossible correlation between totalm ortality and the intensity of antihypertensivetreatmentand the related reduction of systolicb lood pressure. The treatmenteffecton stroke outcome ist he onlys ignificantly changed endpointw hichi smost pronounced in patients withisolated systolichypertension in our analysis. Ass howni nseveralstudies,isolated systolichypertension isknowntobeapredominantr iski ndicatorfor stroke [9, 21] ;t he results herep romotei solated systolic hypertension intothe status of ariskf actorasits treatmentispositivelycorrelated withstroke riskreduction.
Riskreduction forheart failureo f0.49 (95 %0.37 -0.67)wast he largest treatmenteffectobserved here. The generalp revalencei sabout 2-3%,a nd risesin the age group70 -80y ears to1 0-20 % [27] .Antihypertensivetreatmentin the very elderlythus seemstobemore effectivetop reventheart failurethanstroke -afinding whichh asnoty etbeen appreciated elsewhere.
The combined riskf ormorbidity and mortality from cardiovascularconditionsisalsosignificantlyr educed byantihypertensivetreatment.Even when removing the HYVET trial,astatisticallys ignificantr iskreduction isobserved. Thisresultisin line withthe Cochrane Collaboration reviews byMusini etal. and Mulrow etal. [14, 25] b ut notr eported in [13] .Asin most clinical trials,the patients included in the studiesin thismetaanalysisappeared tobeh ealthiert hanthosei nthe globalp opulation,a st he overall ratesof stroke,heart attack,the prevalenceo fd iabetes,smoking and need for nursing careatbaseline werel owcompared too ther studies [3, 28] .
Itiss till controversialh owfarblood pressureshould bel owered in the elderly.Most commonly,140mmHg systolicb lood pressurei ss etast he goal,e. g. in the guidelinesof the ESH/ESC [29] .Based on the large HYVET studyasystolicvalueo f1 50mmHgseemst obe bothp racticaland safe tog uarantee apositivebenefitriskratio. The authors of the JATOS and CASE-Jtrials conducted post-hoc analysesassessing the optimal blood pressure. Inthe very elderly,itcould ben oticed thateventratesrosewiththe reduction of systolicblood pressurel owert han1 40mmHg. Taking the results from HYVET and the post-hoc analysisfrom JATOS and CASE-Jtogether,the preferred treatmentt argetw ould beavaluebetween 140-150mmHgsystolic, withm ore evidenceavailable for150t hanf or140mmHg. Itisobvious thatt reatmentgoalshavetobei ndividualized, and additionalconditions(e. g. diastolicb lood pressure whichshould notbelowered below60mmHg,orexcessiveblood pressured ecreasesu pon posturalchanges) should beconsidered. Ino ur searchwef ound onlyt wo trialsdirectlycomparing strict versus mild treatment [16, 28] .Bothtrialsw ereconducted in Japan. Inthe JATOS trial,mild treatmentled tom eanblood pressure valuesof 145.6/78.1 mmHgand strictt reatmentt ovaluesof 135.9/74.8 mmHg. Inthe strictt reatmentgroup the incidencesof the primary endpointw eresignificantlylower.Inthe CASE-Jtrialcardiovascularr iskwas notdifferentfors ystolicb lood pressuresfrom 140-149 mmHgcompared withthatfors ystolicb lood pressureslowert han1 30 mmHg.
Inthiscontext,the differentialtherapybydifferent agentgroupsr emainslargelyu nclear.Forelderlypatients (aged 65and above),renin-angiotensin system (RAS)blockers and long acting calciumantagonists seem preferable tootherdrugclassessuchasbetablockers (higherincidenceo fd iabetesmellitus,inferiorendpointresults in LIFE [30] )orthiazide-type diuretics(potentiallylife-threatening electrolyted isorders,low compliance,superiority of the combination of ACE-inhibitor/calciumantagonist overACE-inhibitor/thiazide-type diureticin the ACCOMPLISH trial, [ 31] )asr ecommended e. g. in the ESC/ESH guideline [29] .The currentmeta-analysisdid notallowforcomparisonsbetween differentdrugclassesregarding theirendpointefficacy.Intermsof drugclass differentiation,weconducted aregression analysist hatr evealed thats tudies conducted aftert he year2 000 reached amorep ro- nounced decreaseo fsystolicb lood pressure. Thisisin line withthe assumption thatneweragents (RAS blockers and calciumantagonists asopposed todiureticsand betablockers)m aybem oree ffectivethano lderones. Theseresults showthatantihypertensivetherapysignificantlyr educescerebrovascularand cardiovascular morbidity in patients olderthan75years in good generalcondition and withmild tomoderatesystolicand systo-diastolichypertension. The mortalitiesof coronary heart diseaseand cardiovascularevents and the total mortality arenots ignificantlyr educed.
Renalf ailurewasnotconsistentlyr eported oreven considered asexclusion criteria(HYVET)i nthe studies; toanalyserenalf unction separatelyw ould bed esirable ashypertension isastrong riskf actorforr enalf ailure.
Despitethe additionali nclusion of the JATOS trial, thismeta-analysislargelyconfirmst he recentfindings byBejan-Angoulvat etal. [13] but addsmoredetailed information on secondary endpoints.The optimaltreatments izei snoty etclearand should becarefullyconsidered in futuretrialsand clinicalp ractice. Taking this together,the datadescribeani mportantexample for the so-called compression of morbidity,aconcept based on the desirable improvementof quality of life even in end-of-life situationsin whiche xtension of longevity cannotbep rovided.
